Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma

– Ocular Technologies’ key development program asset, Seciera™ for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial.
– Auven to receive $40 million upfront payment, substantial contingent development and commercial milestone payments, and royalties.

Read the full press release

Sun’s press release